Vr Adviser, LLC Altimmune, Inc. Transaction History

Vr Adviser, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 May 15, 2023	BUY	$3.94 - $11.77 $1.46 Million - $4.35 Million	369,306 New	369,306 $4.32 Million
Q2 2022 Aug 15, 2022	SELL	$3.94 - $11.77 $1.54 Million - $4.6 Million	-390,413 Reduced 51.39%	369,306 $4.32 Million
Q1 2022 May 16, 2022	BUY	$5.9 - $9.45 $4.48 Million - $7.18 Million	759,719 New	759,719 $4.63 Million
Q4 2021 Feb 14, 2022	SELL	$8.69 - $12.48 $33 Million - $47.4 Million	-3,800,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$8.43 - $16.81 $2.53 Million - $5.04 Million	300,000 Added 8.57%	3,800,000 $43 Million
Q1 2021 May 14, 2021	SELL	$12.71 - $24.31 $12.7 Million - $24.3 Million	-1,000,000 Reduced 22.22%	3,500,000 $49.5 Million
Q2 2020 Aug 14, 2020	BUY	$2.9 - $10.71 $13.1 Million - $48.2 Million	4,500,000 New	4,500,000 $48.2 Million

208

39.5M

1.94M

1.38M

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $300M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Vr Adviser, LLC, based on Form 13F filings with the SEC.

Stay updated on Vr Adviser, LLC with notifications on news.